全文获取类型
收费全文 | 27527篇 |
免费 | 1906篇 |
国内免费 | 977篇 |
专业分类
耳鼻咽喉 | 430篇 |
儿科学 | 180篇 |
妇产科学 | 406篇 |
基础医学 | 1929篇 |
口腔科学 | 228篇 |
临床医学 | 2260篇 |
内科学 | 2339篇 |
皮肤病学 | 248篇 |
神经病学 | 259篇 |
特种医学 | 2199篇 |
外国民族医学 | 22篇 |
外科学 | 5709篇 |
综合类 | 4190篇 |
现状与发展 | 1篇 |
预防医学 | 693篇 |
眼科学 | 78篇 |
药学 | 1086篇 |
中国医学 | 139篇 |
肿瘤学 | 8014篇 |
出版年
2024年 | 32篇 |
2023年 | 237篇 |
2022年 | 597篇 |
2021年 | 890篇 |
2020年 | 862篇 |
2019年 | 795篇 |
2018年 | 878篇 |
2017年 | 812篇 |
2016年 | 826篇 |
2015年 | 960篇 |
2014年 | 1706篇 |
2013年 | 1252篇 |
2012年 | 1373篇 |
2011年 | 1672篇 |
2010年 | 1452篇 |
2009年 | 1660篇 |
2008年 | 1750篇 |
2007年 | 1827篇 |
2006年 | 1700篇 |
2005年 | 1357篇 |
2004年 | 1221篇 |
2003年 | 1067篇 |
2002年 | 920篇 |
2001年 | 895篇 |
2000年 | 708篇 |
1999年 | 504篇 |
1998年 | 456篇 |
1997年 | 418篇 |
1996年 | 281篇 |
1995年 | 229篇 |
1994年 | 197篇 |
1993年 | 135篇 |
1992年 | 119篇 |
1991年 | 116篇 |
1990年 | 70篇 |
1989年 | 48篇 |
1988年 | 62篇 |
1987年 | 44篇 |
1986年 | 48篇 |
1985年 | 51篇 |
1984年 | 32篇 |
1983年 | 22篇 |
1982年 | 30篇 |
1981年 | 19篇 |
1980年 | 22篇 |
1979年 | 18篇 |
1978年 | 13篇 |
1977年 | 14篇 |
1976年 | 6篇 |
1975年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
头颈部肿瘤CT灌注成像表现与微血管生成因子表达水平的相关性研究 总被引:3,自引:0,他引:3
目的研究头颈部肿瘤CT灌注与肿瘤血管生成因子(VEGF)的相关性。方法对85例共88个(恶性77个,良性11个)头颈部肿瘤术前行CT灌注检查。采用螺旋CT机自带软件绘制感兴趣区(ROI)的时间-密度曲线(TDC)并计算ROI强化峰值(PH)、达峰时间(PT)、平均通过时间(MTT),病灶相对强化峰值(RPH)和灌注量(PF)。其中35例切取与CT灌注靶层面相同的组织切片,行CD34、VEGF抗体免疫组织化学染色,分析肿瘤CT灌注成像表现与微血管密度(MVD)和VEGF表达的相关性。结果(1)头颈部肿瘤CT灌注成像TDC主要有3种类型,77个恶性肿瘤中53个(68.9%)表现为速升速降型;9个淋巴瘤中6个TDC表现为低平型曲线,与68个其他肿瘤中仅有9个为低平型曲线相比差异有统计学意义(P〈0.05)。(2)甲状腺癌呈高灌注,其PF(中位数为82.2ml·min^-1·100g^-1)与淋巴瘤PF(中位数为24.5ml·min^-1·100g^-1)、头颈鳞癌PF(中位数为23.8ml·min^-1·100g^-1)相比差异有统计学意义(P〈0.05)。(3)11个良性肿瘤的MVD均数为(44.7±3.4)条/高倍视野,24个恶性肿瘤的MVD为(49.6±14.8)条/高倍视野,良恶性肿瘤间差异无统计学意义(P〉0.05);VEGF在恶性肿瘤呈强阳性者15个,弱阳性9个;在良性肿瘤呈强阳性1个,弱阳性10个,VEGF的表达强阳性率在良、恶性肿瘤差异有统计学意义(P〈0.01)。(4)MVD(中位数40.0)与PH(中位数26.9)、RPH(中位数14.5)和PF(中位数46.8)有明显相关性(r值分别为0.35、45.49和0.41),VEGF(中位数4.0)表达与MTT(中位数16.7)呈负相关(r=-0.41)。结论CT灌注成像TDC形态对头颈部肿瘤诊断及鉴别诊断有一定的帮助。MVD、VEGF与CT灌注相关,CT灌注成像可以反映肿瘤微循环情况。 相似文献
52.
目的探讨胃癌累及胰腺的外科治疗方法与预后的关系。方法回顾性分析我院1984年6月~2003年10月手术治疗累及胰腺的胃癌120例。结果本组120例中,根治切除组41例,姑息切除组23例,未切除组56例。根治组41例中经病理证实胰腺有癌细胞浸润者30例,占73.2%,淋巴结转移率为85.4%。其中No10、11淋巴结转移率为73.1%。术后102例得到随访,随访率为85%,1、3、5年的生存率分别为:根治切除组为73%、37%、17%,姑息切除组为22%、9%、4%,未切除组为9%、2%、0%。根治切除组1,3年生存率明显高于姑息性切除组和未切除组(P<0.05),5年生存率明显高于未切除组(P<0.01),但与姑息性切除组无显著性差异。姑息性切除组和未切除组1、3年生存率无显著性差异,但5年生存率明显高于未切除组(P<0.01)。结论胃癌累及胰腺的根治切除可提高1,3年生存率,选择合适的适应征是关键。姑息切除有助于改善生存质量,对改善预后意义不大。 相似文献
53.
F. Giangaspero C. Doglioni M. T. Rivano S. Pileri J. Gerdes H. Stein 《Acta neuropathologica》1987,74(2):179-182
Summary The monoclonal antibody Ki-67, which reacts with cells in the active part of the cell cycle, was used to evaluate immunocytochemically the growth fraction in 22 primary brain neoplasms. The percentage of labelled cells reflected the histological grade of malignancy of each neoplasms. High percentage of Ki-67-positive cells were observed in one choroid plexus carcinoma (60%), one primary melanoma of meninges (40%), three medulloblastomas (40%–50%), one anaplastic astrocytoma and six glioblastomas (10%–40%). One ependymoma had 7% positive cells. Rare positive cells (1%) were present in one pilocytic astrocytoma and one ganglioglioma. Except one negative case, the meningiomas (five cases) had values of positivity ranging from 1% to 6%. Two acoustic schwannomas were negative. These results suggest that immunocytochemical staining with the Ki-67 may be a useful method for measuring the growth fraction in brain neoplasms.Supported in part by Associazione Italiana Ricerca sul Cancro and Ministero Italiano della Pubblica Istruzione 相似文献
54.
Yasuyo Shintani Yoshihisa Sawada Takeshi Inagaki Yasuo Kohjimoto Yasunari Uekado Toshiaki Shinka 《International journal of urology》2007,14(2):140-146
AIM: In order to clarify the initial step of the mechanism by which bacillus Calmette-Guérin (BCG) exhibits antitumor activity via the immune response induced in the bladder submucosa after intravesical BCG therapy for human bladder cancer, various cytokines secreted in the urine after BCG instillation were measured. METHODS: After transurethral resection of bladder cancer, a 6-week course of BCG instillation was performed. At the first and sixth weeks' dosings, spontaneously excreted urine was collected before and 4, 8, and 24 h after BCG instillation. The urinary cytokines were determined by Sandwich enzyme-linked immunosorbent assay using monoclonal antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-1beta, IL-8, interferon (IFN)-gamma, and IL-12. RESULTS: After the BCG therapy, various cytokines, such as GM-CSF, TNF-alpha, G-CSF, IL-1beta, IL-8, IFN-gamma, and IL-12 were secreted, comprising the immune response cascade. The mean urinary excretions of GM-CSF and TNF-alpha 4 h after the sixth week's instillation were significantly higher than the pre-instillation levels. There were no significant increases in the urinary IFN-gamma or IL-12 levels between 4 and 24 h after the sixth week's instillation. The TNF-alpha level 4 h after the sixth week's instillation had a strong tendency towards the absence of recurrence, with a mean follow-up of 54.1 months. The Kaplan-Meier curve showed the 2, 5, and 10-year recurrence-free survival rates were 72.4%, 65.8%, and 56.4%, respectively. CONCLUSIONS: We suggested that the urinary levels of TNF-alpha might be essential in antitumor activity after BCG therapy and might play an important role in the prevention of bladder tumor recurrence. 相似文献
55.
Permanent prostate brachytherapy for Japanese men: Results from initial 100 patients with prostate cancer 总被引:1,自引:1,他引:0
Toshikazu Okaneya Shuji Nishizawa Tsuyoshi Nakayama Takayuki Kamigaito Iwao Hashida Noriko Hosaka 《International journal of urology》2007,14(7):602-606
OBJECTIVE: To evaluate the initial results of brachytherapy for prostate cancer with permanent iodine-125 implant in Japan. METHODS: The results obtained with brachytherapy in the initial 100 Japanese patients treated at Nagano Municipal Hospital were reviewed. Patients with a prostate-specific antigen (PSA) level of less than 10 ng/mL and a Gleason's scores of 5, 6, 3 + 4 were classified as having a low risk of recurrence. Patients with a PSA level of 10-20 ng/mL and/or a Gleason's score of 4 + 3 were classified as having an intermediate risk for recurrence. Seventy-eight of the low-risk patients and 19 of the intermediate-risk patients were treated by seed implants alone, or seed implants combined with preceding external radiation, respectively. A total of 53 patients received neoadjuvant hormone therapy. The efficacy and morbidity of brachytherapy were investigated using the serum PSA, International Prostate Symptom Score, quality of life score and uroflowmetry data. RESULTS: The average V100 and D90 obtained by post-implant dosimetry was 94.3 and 113.7%, respectively. Serum PSA decreased gradually after treatment, although it had still not reached a nadir after 1 year. There was little difference of the PSA level between the patients with and without neoadjuvant hormone therapy even at 1 year after seed implantation. There were no PSA biochemical failure or clinical recurrence during the follow-up period. Voiding symptoms worsened until 3 months after treatment, and then gradually improved. Acute urinary retention occurred transiently in one patient (1%). Rectal bleeding and severe diarrhea did not occur. CONCLUSION: Brachytherapy is a feasible and effective option for the treatment of prostate cancer in Japanese men. Brachytherapy may have a different effect in Japanese patients with respect to voiding symptoms. Urinary retention was rare, but voiding symptoms were persistent in Japanese patients. Neoadjuvant hormone therapy deserves investigation to determine whether it can achieve better results, especially in patients with an intermediate risk. 相似文献
56.
胃平滑肌肿瘤的诊断与治疗(附21例临床分析) 总被引:1,自引:1,他引:0
目的:研究旨在评价胃平滑肌肿瘤的生物学行为及其诊治。方法:收集1986~1995年间本科治疗患者,检出平滑肌起源胃肿瘤21例,复习病史、实验室检查、手术及病理报告,以比较良、恶性平滑肌肿瘤的临床特点、生物学活性及处置。结果:病理证实11例胃平滑肌瘤,9例肉瘤及1例子滑肌母细胞瘤。临床特点以腹痛(16/21)、呕血及血便(12/21),以及腹部包块(5/12),腹块主要见于恶性肿瘤中。肿瘤好发于胃体及胃底;肿瘤直径范围自0.5~15cm,肌瘤平均3.9cm,肉瘤平均7.8cm(P<0.05)。外科治疗的原则是局部切除肿瘤及周边2—3cm胃壁组织。在4例有转移的恶性肿瘤采用了姑息治疗措施。结论:区分平滑肌瘤及肉瘤主要标准是临床上局部浸润及转移以及组织学上的有丝分裂指数。肿瘤大于8cm恶性可能大,手术切除范围宜扩大。 相似文献
57.
肺癌患者红细胞免疫功能和T淋巴细胞亚群的检测及临床意义 总被引:10,自引:0,他引:10
作者对62例肺癌患者进行红细胞免疫功能及T淋巴细胞亚群测定,并与20例正常人对照。结果显示:肺癌组红细胞膜C3b受体活性(RBC-C3bRR)、CD3 、CD4 、CD4 /CD8 比值均低于正常人(P<0.05~0.01),红细胞膜的吸附免疫复合物(RBC-ICR)、CD8 均高于正常人(P<0.05~0.01),因此认为红细胞免疫及T淋巴细胞亚群测定对肺癌的诊断、治疗及病情预后估计有一定价值。 相似文献
58.
肿瘤转移相关蛋白在甲状腺乳头状腺癌伴淋巴结转移组织中的原位表达研究 总被引:1,自引:0,他引:1
利用免疫组化ABC法,研究甲状腺乳头状腺癌,甲状腺腺瘤和正常甲状腺组织中的肿瘤转移相关基因蛋白CD44v6,EGFR,转移抑制基因nm23-H1和抑癌基因p53蛋白的原位表达。结果发现CD44v6和EGFR表达上调与肿瘤转移密切相关(P<0.05,P<0.01),而nm23-H1的表达与肿瘤转移抑制密切相关(P<0.01)。这提示肿瘤转移相关基因和转移抑制基因之间的表达失衡是甲状腺乳头状腺癌易发生转移的重要原因。 相似文献
59.
Summary A simple technique of stereotactic craniotomy and intraoperative lesion localisation that uses the Brown-Robert-Wells (BRW) stereotactic frame is presented. The method optimises craniotomy placement and facilitates localisation of small intracerebral lesions. Using the system, 16 patients have had resection of intracranial neoplasms from deep and/or eloquent areas of the brain with no neurological morbidity. 相似文献
60.
C. J. Bowden W. D. Figg N. A. Dawson O. Sartor R. J. Bitton M. S. Weinberger Donna Headlee Eddie Reed C. E. Myers M. R. Cooper 《Cancer chemotherapy and pharmacology》1996,39(1-2):1-8
Introduction: Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis,
but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent. Objective: This clinical trial of suramin was undertaken as a phase I/II study in patients with hormone-refractory prostate cancer,
with the hypothesis that the intensity of therapy with suramin could be increased significantly if measures were undertaken
to maintain the plasma concentrations of the drug under 300 μg/ml. Methods: We report the clinical results of this trial, wherein patients were treated at three different targeted plasma suramin concentrations
(275, 215 and 175 μg/ml) for varying periods of time (2, 4 or 8 weeks), with delivery of the drug by continuous intravenous
infusion. Results: The major toxicity observed in this trial was neurologic, consisting of a motor and sensory peripheral neuropathy that resulted
in both paresis and paralysis of the limbs. Nearly all of this severe (CTEP grade III, IV) neurologic toxicity was observed
in the patients treated at a plasma suramin concentration of 275 μg/ml for 4 or more weeks. A single patient treated at 215 μg/ml
for 8 weeks developed moderate (CTEP grade III) proximal lower extremity weakness, and no patient treated at 175 μg/ml developed
this toxicity. The second most common toxicity observed was infection of the central venous catheter. The overall response
rate for all of the evaluable patients was 17% (13 of 75 patients). In addition, prostate-specific antigen (PSA)-defined responses
were observed in six patients receiving therapy at 175 μg/ml, but these responses were confounded by cessation of therapy
with flutamide during suramin treatment. Conclusions: In summary, although plasma suramin concentrations were maintained below 300 μg/ml, neurologic toxicity nonetheless occurred
with high frequency in patients treated at 275 μg/ml for 4 or more weeks. Therapy at 215 and 175 μg/ml was in general well
tolerated, but central venous catheter-related infection, as well as the inconvenience and expense of continuous infusional
therapy, make this method of drug delivery impractical. Only moderate antitumor activity was observed during this trial, but
it is possible that both continuation of flutamide and flutamide withdrawal during suramin therapy confounded the assessment
of suramin’s activity in hormone-refractory prostate cancer.
Received: 9 June 1995/Accepted: 18 March 1996 相似文献